Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

J&J COVID-19 vaccine protects against Delta variant

By Brian Buntz | July 2, 2021

Johnson & JohnsonJohnson & Johnson (NYSE:JNJ) has announced that a single shot of its COVID-19 vaccine offers significant protection against the transmissible Delta variant. The vaccine also provides an immune response lasting at least eight months.

The announcement coincides with the company filing two preprint studies to bioRxiv. The first analyzes blood samples from eight patients in the company’s Phase 3 ENSEMBLE study, which it used to win emergency use authorization in the U.S. That study concluded that a single dose of the vaccine led to a higher neutralizing antibody activity against the Delta variant than the Beta variant (B.1.351) that first emerged in South Africa.

Rival Moderna is developing a vaccine known as mRNA-1273.351 based on the Beta variant.

J&J also announced that its vaccine elicited a robust immune response to other common SARS-CoV-2 variants.

The company also said that its vaccine led to a strong neutralizing antibody response that did not wane over eight months. Instead, “we observe an improvement over time. In addition, we observe a persistent and particularly robust, durable cellular immune response,” said Dr. Mathai Mammen, global head, Janssen Research & Development, in a statement. In particular, the recent data indicates that T-cell responses lasted over the eight-month timeframe.

The recent data regarding the durability of the immune response indicates that most people who are fully vaccinated will likely will not require boosters in the short-term.


Filed Under: clinical trials, Drug Discovery, Infectious Disease
Tagged With: clinical trials, coronavirus, covid-19, COVID-19 vaccine, COVID-19 vaccine trial, COVID-19 vaccines, Johnson & Johnson, Moderna, SARS-CoV-2 variants
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

lab microscope
Accelerating R&D with FAIR data
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio
Axcella
Axcella touts positive results from Phase 2a long COVID study
artificial intelligence
Defining complexity: A framework to identify complex clinical trials and set them up for success

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50